# An Introduction to Stock Valuation Brian Donovan, CBV 

August 2017

## Background:

## "Risk comes from not knowing what you are doing." - Warren Buffet

Buying stocks without understanding their value is like buying a (car, set of golf clubs, vacation) without asking the (price, model, location) first. How do you know you are getting a good deal if you don't know the value?

This e-book is an overview of valuation. Its purpose is to help you understand how to value stocks. Picking stocks, once you know this, is an easier process as it gives you a level of confidence that you are purchasing stocks that have a value you have determined based on the risks you understand.

The material can be a bit dry at times; we'll try and keep it light.

## Who should read this book?

This book is an introduction to valuation so there is some level of understanding that will be needed (and can easily be obtained). The book is of value:

- If you are investing but are not sure how the stocks you own are valued
- If you are aware of financial statements, may recognize Revenue and Net Income but not much else and want to expand that knowledge as it pertains to the Stock Market

| Novice Investor | Intermediate | Day Trader | CPA Level | CFA Level |
| :--- | :--- | :--- | :--- | :--- |
| Highly valuable but <br> requires additional <br> work to <br> understand some <br> financial terms | Greatest gain from <br> this e-book will <br> happen for <br> investors with <br> some financial <br> knowledge | Book is valuable <br> for day traders <br> looking to add <br> fundamental <br> knowledge | CPA's that have <br> not analyzed <br> stocks will find this <br> a fast easy read | Limited value. |
| CFA's have the <br> knowledge to <br> write this ebook |  |  |  |  |

There are many other parts to understanding what stocks to buy (or sell) and we will cover some of those in future editions, specifically analyzing a company's financial statements and ratios to understand what risks we need to be aware of (does the company have too much debt compared to its industry, does the company face a liquidity crunch in its short term financing...) We do touch on ratios here and introduce some limited financial statement analysis.

To run a valuation on a company try it here: https://stockcalc.com/get valuation report.aspx

## About the Author:

Brian is the President of StockCalc (www.stockcalc.com) a fundamental valuation website for retail Investors and Investment Advisors. Brian is a Chartered Business Valuator (CBV), a Canadian valuation designation (www.cicbv.ca)

## Table of Contents

Background: ..... 2
About the Author: ..... 2
Introduction: ..... 5
Technical and Financial Terms: ..... 5
Equity and Enterprise Value: ..... 6
Financial Statements: ..... 7
Book Value and Market Value ..... 9
Discount Rates: ..... 10
Valuation Methods: ..... 13
Cash Flow Methods: ..... 13
Asset Based Valuation: ..... 17
Adjusted Book Value: ..... 17
Liquidation Value ..... 19
Comparable Valuation: ..... 20
Summary: ..... 24
Comprehensive Examples: ..... 25
Johnson \& Johnson: ..... 25
Literature Cited: ..... 33

## List of Figures:

Figure 1. Enterprise vs Equity Value ..... 6
Figure 2. Enterprise vs Equity Value: So What? ..... 7
Figure 3. Balance Sheet for Johnson \& Johnson (JNJ:NYS ) ..... 8
Figure 4. Five year Price performance for JNJ:NYS (Source Yahoo Finance) ..... 10
Figure 5. Overview of Discount Rates ..... 11
Figure 6. Calculating Weighted Average Cost of Capital ..... 12
Figure 7. Calculating Weighted Average Cost of Capital JNJ:NYS ..... 12
Figure 8. Fundamental Valuation Methods ..... 13
Figure 9. Cash Flow Based Valuation Components ..... 14
Figure 10. Discounted Cash Flow Set-up ..... 15
Figure 11. Discounted Cash Flow: Value per Share Calculation ..... 16
Figure 12. Asset Based Valuation Method ..... 17
Figure 13. Adjusted Book Value Approach ..... 18
Figure 14. Liquidation Analysis ..... 19
Figure 15. Comparable or Relative Valuation Method ..... 20
List of Tables:
Table 1. Book Value of Equity for JNJ:NYS ..... 9
Table 2. Historic PB ratios for JNJ:NYS ..... 9

## Introduction:

If you want to learn how to value stocks, this introduction to valuation is designed for you. In this ebook we review a number of valuation techniques and work though some current examples. Once you have worked though the text and examples you will be able to apply the frameworks to the stocks you are interested in.

This is (hopefully) a practical book you can use to understand how to value stocks. Stock valuation is a methodical process that helps you understand the boundaries of what a company is worth and lets you zone in on the ultimate value. Values changes when the inputs change.

There are a few things I would like to start with before you jump into the details below:

Valuation is based on:

- Assumptions about the future of the company
- Assumptions about how it compares to other companies
- Assumptions (or assessments, much better) of the value of the assets the company has and the debts and obligations it owes

Those 3 statements capture the 3 broad ways we look at valuation

- On the basis of Cash Flow
- On the basis of Comparable Companies
- On the basis of the Assets the company has

We will go over each of these. First let's start with a few terms to set the stage:

## Technical and Financial Terms:

This book is being written for someone new to valuation. Our online valuation company (www.stockcalc.com) keeps a help file at your ready. The dictionary is found here and it contains both definitions and calculations: https://www.stockcalc.com/Help/index.html\#Financial\ Dictionary

There are also many great resources in the web including: http://www.investopedia.com/

Our YouTube StockCalc Channel also has a number of videos you should find educational:


How to Value Stocks


Facebook Valuation Overview

We need to set the stage with a few definitions: equity vs enterprise value, book vs market value

## Equity and Enterprise Value:

We hear the term equity a lot when dealing with the stock market.

- Equity in the stock market context is the stock (share certificates) that gets traded between investors and can be common or preferred (common stock, preferred stock).
- Equity on financial statements (Balance Sheet specifically) is part of the value of the company and includes the amount of funds contributed by the owners plus the retained earnings (total amount of gains and losses of net income the company has had over time) (Source:
Investopedia)

Enterprise Value is the total value of the company and includes both the equity in the company as well as the debt the company has. Enterprise value is generally thought of in market value not book value terms. i.e. we want to know what someone would pay for the company.

Enterprise Value = Equity Value + Debt Value

## Valuation Basics

## Enterprise Value versus Equity Value

Equity Value (Think Value of the stock)
Common Stock Price* \# Common Shares Outstanding+
Preferred Stock Price* \# Preferred Shares Outstanding

Enterprise Value (Think Value of the Company)
Value of the Equity Plus Value of the Debt or
Equity Value = Enterprise Value - Debt

Figure 1. Enterprise vs Equity Value

## So What?



Well 2 things actually:

1) We can calculate the value of the Equity directly (equity is what we want to know because we can calculate stock price from it) or
2) If we can calculate the total value of the company, we can subtract the debt to get the value of the equity (so we can calculate stock price from it)

## Valuation Basics

## Enterprise Value versus Equity Value

## So What?

## Can Determine Equity or Enterprise Value

Discount rates differ
(Equity Value per share is what we want to know)

Also note the difference between Book Value (as shown on the Balance Sheet) and Market Value (what it would sell for)

Figure 2. Enterprise vs Equity Value: So What?

## Financial Statements:

There are 3 financial statements of interest to the new investor: (Source: Investopedia)

Income Statement: a financial statement that reports a company's financial performance over a specific accounting period. Financial performance is assessed by giving a summary of how the business incurs its revenues and expenses through both operating and non-operating activities.

Balance Sheet: A balance sheet is a financial statement that summarizes a company's assets, liabilities and shareholders' equity at a specific point in time. (Sample on next page)

Cash Flow Statement: a financial statement that shows how changes in balance sheet accounts and income affect cash and cash equivalents, and breaks the analysis down to operating, investing and financing activities.

| Balance Sheet | Johnson \& Joh |  | December 3 | 2016 |
| :---: | :---: | :---: | :---: | :---: |
| Line Item USD Millions | 31-Dec-13 | 31-Dec-14 | 31-Dec-15 | 31-Dec-16 |
| Total Assets | 132683 | 131119 | 133411 | 141208 |
| Current Assets | 56407 | 59311 | 60210 | 65032 |
| Cash And Cash Equivalents | 20927 | 14523 | 13732 | 18972 |
| Other Short Term Investments | 8279 | 18566 | 24644 | 22935 |
| Receivables | 11713 | 10985 | 10734 | 11699 |
| Inventory | 7878 | 8184 | 8053 | 8144 |
| PrepaidAssets | 4003 | 3486 | 3047 | 3282 |
| Deferred Income Taxes | 3607 | 3567 | 0 | 0 |
| Total Non Current Assets | 76276 | 71808 | 73201 | 76176 |
| Gross PPE | 37133 | 36685 | 36648 | 37773 |
| Accumulated Depreciation | -20423 | -20559 | -20743 | -21861 |
| Net PPE | 16710 | 16126 | 15905 | 15912 |
| Goodwill | 22798 | 21832 | 21629 | 22805 |
| Intangibles | 27947 | 27222 | 25764 | 26876 |
| Other Non Current Assets | 8821 | 6628 | 9903 | 10583 |
| Total Liabilities | 58630 | 61367 | 62261 | 70790 |
| Current Liabilities | 25675 | 25085 | 27747 | 26287 |
| Payables | 7036 | 8133 | 7418 | 7889 |
| Current debt | 4852 | 3638 | 7004 | 4684 |
| Non Current Liabilities | 32955 | 36282 | 34514 | 44503 |
| Long Term Debt | 13328 | 15122 | 12857 | 22442 |
| Total Equity | 74053 | 69752 | 71150 | 70418 |
| Stockholders Equity | 74053 | 69752 | 71150 | 70418 |
| Preferred Stock | 0 | 0 | 0 | 0 |
| CapitalStock | 3120 | 3120 | 3120 | 3120 |
| Common Stock | 3120 | 3120 | 3120 | 0 |
| Treasury Stock | 15700 | 19891 | 22684 | 28352 |
| Retained Earnings | 89493 | 97245 | 103879 | 110551 |
| Other Equity | -34260 | -50504 | -58533 | 0 |
| Total Liabilities and Total Equity | 132683 | 131119 | 133411 | 141208 |

Figure 3. Balance Sheet for Johnson \& Johnson (JNJ:NYS )

## Book Value and Market Value

Want to spend a bit of time here as this can be confusing for new investors.

- On the balance sheet we see the value of items at the time they are entered into the accounting system. (Purchased a computer for $\$ 1000$ - entered it into the accounting systems as a $\$ 1000$ computer. Its book value is $\$ 1000$ on the balance sheet). These values get adjusted each year by how much the asset depreciates.
- The value on the balance sheet is called book value and the value someone would pay for that item is called market value.
- Equity is what we want to know to calculate the value of a stock (the market value of equity specifically - we have the book value of equity on the balance sheet).
- You also have heard of the ratio "Price to Book Value". Since we know the values recorded on the balance sheet are book values, a Price to Book value ratio is the amount we would multiple the book value on the balance sheet by to get a Market value (aka Price).

We see the Dec 31, 2016 Equity Value on the balance sheet above is 70418 (in 000000 's of $\$$ ). If we divide that equity value by the number of shares outstanding we get the book value per share for the company. (\$26.02).

Table 1. Book Value of Equity for JNJ:NYS

| Book Value of Equity for Johnson \& Johnson as of Dec 31 2016 |  |
| :--- | ---: |
| Equity on Balance Sheet (000's) | 70418000 |
| Number of Shares Outstanding (000's) | 2706511 |
| Book Value Per Share | $\$ 26.02$ |

Since companies do not report their financials until weeks (months) after the end of the fiscal period the price to book ratio will use the most recent value we have (ie Dec $31^{\text {st }}$ ). We can backtrack to the date of the most recent financials so we are always using the same date to compare over time. For example, on Dec 31, 2016, JNJ's stock was trading at $\$ 112.25$. If we divide that price per share by the book value per share we get a Price to Book value of 4.31 . This is at the high end of its PB range for the last 10 Years

Table 2. Historic PB ratios for JNJ:NYS

| Historic Price to Book Values for Johnson \& Johnson 2007-2016 |  |  |  |  |  |  |  |  |  |  |
| :--- | :---: | :---: | :---: | :---: | :---: | :---: | :---: | :---: | :---: | :---: |
| Year | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 | 2010 | 2009 | 2008 | 2007 |
| P:B Ratio | 4.31 | 3.97 | 3.80 | 3.70 | 3.00 | 2.91 | 3.00 | 3.51 | 3.90 | 4.37 |

Is JNJ Expensive on a Price to Book Ratio?
Based on the historic values we would have to conclude Yes.
We see from the high in 2007 of 4.37 (and we could go further back) JNJ's book value per share dropped to below 3.00 during 2010-2012 period. Its stock price has doubled since then with it book value increasing about 50\%. But that is not the whole picture, rather 1 data point in a valuation.

$123.51-0.44(-0.35 \%)$
At close: 5 May 4:04PM EDT


Figure 4. Five year Price performance for JNJ:NYS (Source Yahoo Finance)

## Discount Rates:

Now we need to introduce discount rates: (A discount rates is an interest rate or fee charged, i.e. a cost)

As we mentioned above the company's total value (Enterprise Value) consists of debt and equity. Each of these has a cost to obtain them. Let's start with debt as it is the more common and easier to understand.

Debt to a company is the same as a mortgage or car loan to a consumer. Both have to pay principal and interest on the debt. For companies, interest debt is paid before taxes so it is considered a pre-tax cost (noted as we will make an adjustment for this later)

Equity has a cost as well. Think of it in this manner
You start a business and bring in a shareholder for say $25 \%$ of the value of the equity so you have some money to buy equipment with or pay salaries.

From the investors perspective the cost of equity can be thought of as the return they would expect to get by investing (buying stock) in the company. In the public markets an investor that buys a blue chip stock expects a lower but safer return than one that buys stock in a new technology company for example. The return would need to be higher (much) in the technology company to offset the risk involved.

If a company has preferred shares their cost is the dividend paid (expressed as a \%)

5 Blue chip stocks that increase in price by $6 \%, 8 \%, 8 \%, 9 \%$ and $4 \%$ or 5 Technology companies that return $\% 52,18 \%,-22 \%, 76 \%$ and $-100 \%$ (ie went bankrupt)

If you invested $\$ 1000$ in each of the 10 companies above the 5 blue chips would have returned $\$ 60+\$ 80+\$ 80+\$ 90+\$ 40=\$ 350$ (or now be worth $\$ 5350$ )

The 5 Technology companies would have returned
$\$ 520+\$ 180-\$ 220+\$ 760-\$ 1000=\$ 240$ (or now be worth $\$ 5240$ )

## Valuation Basics

## Discount Rates - Used to Calculate Present Value

## Cost of Common Equity (Ke)

Think return investors expect Cost of Preferred Equity (Kp)

Think Dividend Rate of Preferred Stock

## Cost of Debt (Kd)

Interest paid / Debt Outstanding
Is an after tax rate

Figure 5. Overview of Discount Rates

To calculate these rates we do the following:
Cost of Debt = (Interest paid / Value of the debt) * (1-Tax Rate)
Cost of Preferred stock = Dividends paid / Price of Preferred stock
Cost of common equity = This is calculated using a formula that takes into consideration how the stock moves with the overall market, risk of equity over debt and other company specific risks. The formula looks like this but we won't go any deeper at this point.

Cost of Equity (Ke) = Risk free rate + Beta * (Market Risk Premium) + Company Risks

We combine these costs to come up with a value we refer to as WACC or Weighted Average Cost of Capital. The WACC is simply a weighting of the debt and equity for the company times their respective
costs. We use the WACC if we are valuing the company on an Enterprise basis or use just the Cost of Equity if we are valuing the equity directly.

## Valuation Basics

Discount Rates
Weighted Average Cost of Capital (WACC)
\% Common Equity * Ke +
\% Preferred Equity * Ke +
\% Interest Bearing Debt * Kd * (1-Tax Rate)
WACC is used for Enterprise Value
Ke is used for Equity Value
stockcalc
Figure 6. Calculating Weighted Average Cost of Capital

## Weighted Average Cost of Capital

Company: JNJ:NYS

| Component | Value | \% | K | Cost Of |
| :---: | :---: | :---: | :---: | :---: |
| Common Equity | 334,713,834,252 | 93.00 | Ke | 8.22 |
| Debt (Book Value) | 26,989,000,000 | 7.00 | Kd | 2.24 |
| Preferred (Book Value) | 0 | 0.00 | Kp | 0.00 |
| Enterprise Value | 361,702,834,252 | 100 |  |  |
| Weighted Average Cost of Capital |  |  | WACC | 7.80 |

Figure 7. Calculating Weighted Average Cost of Capital JNJ:NYS
It was important to review that information as now we have the pieces we need to start to do valuation.

## Valuation Methods:

We are going to go over 3 valuation methods that are commonly used:

- Cash Flow
- Comparable Companies
- Assets


## Valuation Methods

## Fundamental Approaches

- Cash Flow Based Valuation

Discount Projected Cash Flows

- Asset Based Valuation (Adjusted Book, Liquidation)

Market Values of Assets - Liabilities

- Relative or Comparable Valuation

Value based on Comparable Companies

Figure 8. Fundamental Valuation Methods

## Cash Flow Methods:

We will look at Cash Flow methods first

Cash flow based valuations can take the form of a discounted cash flow where we project cash flows in to the future and discount them all back to the present using the WACC we calculated above or capitalized cash flows where we assume an average cash flow for the company and capitalize it using the WACC. We will go over a discounted cash flow approach here as it is more complex.

First - What is Cash Flow? It is the cash available to the company after taxes and capital expenses (buildings, equipment) have been paid. We refer to this as Free Cash Flow or cash flow that is freed up and available to the company.

To do a discounted cash flow we need

- Cash Flows
- WACC

To calculate value per share we also need

- Interest Bearing Debt
- Number of Shares

We also need to understand how long we are projecting the cash flows for at which point we create a value we refer to as the terminal value where were assume a steady state cash flow. For companies that go through economic cycles like commodity based companies (oil, gold, forest products for ex) we need to project cash flows though the cycle whereas companies that have steady (flat, rising constantly, declining constantly) cash flows we only need a few years of cash flows prior to creating the terminal value.

## Valuation Methods



Figure 9. Cash Flow Based Valuation Components

So if we look at the example below for the Widgets Company we see how to set up a discounted cash flow. We have (an assumed) cash flow of 70, 80, 90 and 100 million (MM \$) in years 2016, 2017, 2018 and 2019. Starting in the year 2020 we assume the cash flow will be steady at 105 (or $5 \%$ above the 2019 value)

We stated at the first of this e-book we need to make assumptions. For a DCF we need assumptions about these cash flows and when and how much the terminal value will be. These values are based on analysis of the company, the industry it is in and any other factors that may affect it.

## Valuation Basics

| Discounted Cash Flow Valuation |  |  |  |  |  |
| :---: | :---: | :---: | :---: | :---: | :---: |
| Widgets Inc. | 1 | 2 | 3 | 4 | 5 |
| WGTS:NYSE | 2016 | 2017 | 2018 | 2019 | Terminal |
| Cash Flow (MM's) | 70 | 80 | 90 | 100 | 105 |
| Discount Rate | 10\% | 10\% | 10\% | 10\% | 10\% |
| Present Value | 0.91 | 0.83 | 0.75 | 0.68 | 0.62 |
| PV Cash Flow | 64 | 66 | 68 | 68 | 65 |
| Terminal Value * | (Assuming 2\% long term Growth rate) |  |  |  | 815 |
| Enterprise Value |  |  |  |  | 1081 |
|  |  |  |  |  |  |
| * Terminal Value Calculation |  | PV CF * ( 100 / (WACC - Growth Rate )) |  |  |  |

Figure 10. Discounted Cash Flow Set-up

You see the next line in Figure 10 is the Discount rate. If the cash flow is before interest payments we will use WACC, if after we use just the Cost of Equity. This is tied to the Enterprise value versus Equity value discussion from above. Are we valuing just the equity or are we valuing the Enterprise and removing the debt after to get the equity.

The present value factor line is calculated as follow:
$1 /(1+\text { discount Rate })^{\wedge}$ year
Example for Year 3: $1 /(1+.1)^{\wedge} 3=0.75$

The present value factor discounts the cash flow back to today, i.e. what is that future cash flow worth in todays terms. We then multiple the Cash flow value by the present value factor to get the Present Value of Cash Flows line values

Next step is to determine the Terminal Value - For that we need a Terminal growth rate which is the very long term growth rate for the company under the assumption the company will survive forever. For that reason, and the fact most companies do not survive forever, the terminal growth rates tend to be a small number like 2 or $3 \%$. (There is a lot of literature on this of you are interested.)

The terminal value is calculated as 100 / (WACC - Terminal Growth Rate)

In this example therefore $100 /(10-2)=12.5$

We then add up all the Present Values from year 1 to 4 plus the terminal value to give us the Enterprise Value (1081 in our example)

To Calculate the Equity value therefore we need to subtract the interest bearing debt which we have assumed to be 300 million in this example leaving $\$ 781$ million in Equity. If there is Preferred Equity (preferred stock) those preferred shareholder get paid before common shareholders if the company was being liquidated so we removed the value of the preferred stock prior to dividing by the number of common shares outstanding to get a value per share. In our example we are (assuming) using book values (from the balance sheet) for both debt and preferred stock. In reality we would use market values for both which would require calculations as well. A minority of companies ( $10 \%$ or so) have preferred stock.

## Valuation Basics

## Discounted Cash Flow Valuation

| Widgets Inc. |  |  |  |  |  |
| :--- | :---: | :---: | :---: | :---: | :---: |
| WGTS:NYSE | 2016 | 2017 | 2018 | Terminal |  |
| Enterprise Value |  |  |  |  | 1081 |
| Debt (assume) |  |  |  |  | 300 |
| Equity Value |  |  |  |  | 781 |
| Preferred Equity |  |  |  |  | 100 |
| Common Equity |  |  |  |  | 681 |
| Shares Outstanding |  |  |  |  | 50 |
| Value per Share |  |  |  |  | $\$ 13.61$ |

Figure 11. Discounted Cash Flow: Value per Share Calculation

That is the process for a discounted cash flow. You see there are some numbers we can easily get from the financial statements and there are assumptions and research required to get the cash flows, growth rates and discount rates


## Asset Based Valuation:

Another way to value a company is to add up the value of the assets it has and remove the value of the debts and obligations. This concept is simple in theory but complicated in practice as it is difficult to obtain the market value of the assets and liabilities for even a small company. With that there are ways we can look at the company and determine its value using it's balance sheet and its historical price to book ratio as we introduced above.

We will cover 2 asset based valuations both based on the same foundation:

## Adjusted Book Value:

In the first method we look to adjust the balance sheet to reflect market values from the book values (we call this adjusted book value) presented there. We can try and do this line by line if we are very familiar with the company or we can look at historic price to book ratios and apply them to the current balance sheet to adjust those book values to market values.

The second method builds on the first: Once we have calculated an adjusted book value for the company we can determine the value that is available to common shareholders if the company was going through a liquidation by removing costs associated with a bankruptcy.

## Valuation Methods

| Asset Based Valuation |
| :---: |
| Adjust the Balance Sheet to Reflect |
| Adjusted Book Value |
| Update Assets and Liabilities on the Balance Sheet |
| to reflect current market conditions | | Liquidation Value |
| :--- |
| Update Assets and Liabilities on the Balance Sheet <br> to reflect current market conditions + determine <br> gains/losses during a liquidation/bankruptcy |

Figure 12. Asset Based Valuation Method

Lets start with a simple example of adjusting the book value as you see in Figure 13.

## Valuation Basics

## Asset Based Valuation - Adjusted Book Value

| Balance Sheet Summary | Book Value | Market Value |
| :--- | :---: | :---: |
| Total Assets | 9000 | 9800 |
| Current Assets | 1000 | 800 |
| Fixed Assets | 8000 | 9000 |
| Total Liabilites + Equity | 9000 | 9800 |
| Current Liabilities | 1500 | 1500 |
| Non-Current Liabilities | 6500 | 6500 |
| Equity (remaining) | 1000 | 1800 |
| Shares Outstanding | 1000 | 1000 |
| Value Per Share | $\$ 1.00$ | $\$$ |

Book Value - As shown on Balance Sheet
Market Value - Value if sold on open market

Figure 13. Adjusted Book Value Approach

## Liquidation Value:

Next we look at the same company if it was undergoing a liquidation (or bankruptcy). We start with the adjusted book value and add or remove revenues and expenses associated with a liquidation. In the example below we show line items like:

Disposition costs: costs incurred to sell the assets of the company Profit or Loss during liquidation: Net income or loss experienced during the liquidation Liquidation Costs: these can be other costs associated with the liquidation including selling inventory at a discount or walking away from receivables
Taxes: if there is revenue being generated during the liquidation there may be a tax implication that we need to account for

## Valuation Basics

## Asset Based Valuation - Liquidation Value

| Assets | 9800 |
| :--- | ---: |
| Disposition Costs | 250 |
| Liabilities | 8000 |
| Net | 1550 |
| \# Months to Liquidate | 6 |
| Profit/Loss During | -600 |
| Liquidation Costs | 200 |
| Taxes | 262 |
| Equity Remaining | 488 |
| Preferred Shares | 0 |
| Equity for Common | 488 |
| Shares Outstanding | 1000 |
| Liquidation Value per Share $\$$ | 0.49 |

Figure 14. Liquidation Analysis

So in the example above we had a book value of $\$ 1.00$ per share, a Market value of $\$ 1.80$ per share and a liquidation value of $\$ 0.49$ per share. It is obviously important if we invest in a company like this we want to see it ongoing and not go through a liquidation.

## Comparable Valuation:

Using Comparable (also called Relative valuation) methods allows us to value 1 company using values or ratios from other companies that we average to create 1 common value. To do this we want to use companies as similar as possible to the company we are generating a value for.

To calculate the price of 1 company from other companies we first need to select companies that are as similar to the chosen company as we can. That means

- Similar Industry
- Similar size
- Similar geography
- Similar financial conditions (debt level for example)

It is not reasonable to compare a small technology company for example to Apple given Apples size, reach, marketing power, sourcing power, financial power... we want to try and find similar companies.

## Valuation Methods



Figure 15. Comparable or Relative Valuation Method
There are 5 ratios we are using to value the company we are interested in. Lets review those

PE RATIO: (Price to Earnings Ratio) This is a very commonly used ratio that is calculated by taking the price of the stock and dividing by the (most recent generally but can be any time point) 12 months Earnings per share for the company. Earnings per share is calculated as Net Income (Income Statement) divided by fully diluted number of shares of the company.

Stock Price / Earnings per Share

PB Ratio: (Price to Book Ratio) This is also a very commonly used ratio that is calculated by taking the price of the stock and dividing by the (most recent generally but can be any time point) 12 months Book Value of the company. If you recall book value is the value on the financial statements. The Book value for a company is the Common Shareholder's Equity found on the balance sheet and consists of the

PS RATIO: (Price to Sales Ratio) This is another common ratio that is calculated by taking the price of the stock and dividing by the (most recent generally but can be any time point) 12 months Total Sales per share for the company.

PCF RATIO: (Price to Cash Flow Ratio) This is also a relatively common ratio that is calculated by taking the price of the stock and dividing by the (most recent generally but can be any time point) 12 months cash flow per share for the company. You saw reference to cash flow above in the discounted cash flow section of this book.

EV2EBITDA (Enterprise Value to EBITDA) This is also a common ratio used to value companies and is calculated by taking the Enterprise Value of the company (we discussed Enterprise Value above) and dividing it by the EBITDA (Earnings before Interest, Taxes, depreciation and Amortization)

It is worth noting where EBITDA and Net Income are on the Income Statement because they have implications on how we value a company directly with these ratios.

## Earnings v EBITDA

PE ratio uses net income, or the accounting income remaining after all other costs are paid (salaries, materials, interest, taxes and depreciation)

EV2EBITDA uses EBITDA in the denominator which does not include interest, taxes and depreciation.

If you think about this for a minute, Earnings takes into account the interest payments we make on the debt whereas EBITDA does not.

So let's look at a detailed example for Johnson \& Johnson (JNJ:NYS)

To calculate the valuation for JNJ we are starting with these ratios above for 5 similar companies: AbbVie, Bristol-Myers Squibb, Eli Lilly, Merck \& Co, Pfizer

To price our company, we use the 5 ratios we have above and calculate the average values for each of those ratios. We then multiply the average ratios by the appropriate measure (earnings per share, sales per share, EBITDA) to generate a value for our company for each of the 5 ratios.

We can then average the 5 calculated values to come up with a comparable value for our company or if the industry warrants, we can use some of the 5 ratios to calculate the value.

In the lower table we show the 5 ratio values for each of these companies along with their average and the values for JNJ on the far left. In the upper left box we show the current per share values for JNJ and in the upper right box the calculated values.

| Company JNJ:NYS End Date <br> Value <br> Earnings/Share $\$ 5.93$ | Price Based on <br> Comps | Adjustment <br> Factor (\%) |
| :--- | :--- | :--- | :--- |
| Book Value/Share | $\$ 25.98$ | $\$ 169.16$ |


| JNJ:NYS | Ratios Used | Average <br> Values | ABBV:NYS | BMY:NYS | LLY:NYS | MRK:NYS | PFE:NYS |
| :---: | :--- | :--- | :---: | :---: | :---: | :---: | :---: |
| 20.82 | PE Ratio | 28.53 | 18.17 | 19.46 | 31.81 | 44.21 | 28.99 |
| 4.75 | PB Ratio | 8.63 | 22.64 | 6.41 | 6.46 | 4.26 | 3.39 |
| 4.79 | PS Ratio | 4.27 | 4.19 | 4.71 | 4.11 | 4.36 | 3.95 |
| 18.35 | PCF Ratio | 17.40 | 15.27 | 23.87 | 17.96 | 16.74 | 13.14 |
| 15.58 | EV to EBITDA | 22.85 | 15.17 | 14.83 | 26.64 | 33.89 | 23.72 |

The average PE Ratio for the 5 comparable companies is 28.53 and JNJ's PE at this time is 20.82. If we take JNJ's current Earnings per share value of $\$ 5.93$ and multiple it by the average value of 28.53 we get a relative or comparable PE based valuation of $\$ 169.16$ for JNJ. We do this over the 5 ratios to get an average and not have 1 value skew the result dramatically. If we have values we think need to be dropped because they are excessively high or low we can do that as well. (Ex: the PB Ratio for ABBV is much higher than the rest and could be removed. Dropping ABBV's PB ratio reduces the calculation from \$224.24 down to \$133.27)
(Note: as we mentioned above EBITDA is pre-interest so we need to subtract the debt/share from EV2EBITDA to have it on the same level as the other 4 ratios.)

Once this is done we can average the calculated values to get a valuation for JNJ of $(169.16+133.27+109.96+117.08+189.23) / 5$ \$143.74

JNJ is trading in the $\$ 125$ range which implies on a relative basis it is undervalued by $15 \%$.


Not immediately. What would be helpful first is: Does JNJ always look undervalued compared to this group? We could rerun this calculation for the last 3-5 years to see if this is the trend or we can look at JNJ's ratios compared to its industry:

| Ratio | JNJ <br> NYS | Healthcare <br> Drug Mfg | \% <br> Difference |
| :--- | :---: | :---: | :---: |
| P:E | 16.74 | 20.69 | $81 \%$ |
| P:B | 3.57 | 4.31 | $83 \%$ |
| P:S | 3.24 | 3.11 | $104 \%$ |
| P:CF | 13.17 | 14.89 | $88 \%$ |
| EV:EBITDA | 10.18 | 8.65 | $118 \%$ |
| Average |  |  | $95 \%$ |

On average over the last 10 years JNJ's ratios have been $95 \%$ of the average for the industry it is in. Based on that, if we reduced the valuation of $\$ 143.74$ by $5 \%$ we still get $\$ 136.55$ or a $10 \%$ undervaluation compared to the industry.

Notes and cautions: This comparable methods works well if you have companies that are similar as noted above and also companies that are generating revenue and earnings. Companies that have no revenue are difficult to value using this method as the method is based on revenue or earnings based ratios. In order to do this we would have to make revenue or earnings assumptions for our company.

We have constructed another method for valuing those companies in StockCalc using changes in price over the last 12 months, net PPE and cash and book values.

## Summary:

This introduction to valuation is designed for users who what to understand fundamental valuation and how it is used to value stocks. In this e-book we review a number of valuation techniques and work though current examples.

Valuation is or has to be based on:

- Assumptions about the future of the company
- Assumptions about how it compares to other companies
- Assumptions (or assessments, much better) of the value of the assets the company has and the debts and obligations it owes

Those 3 statements capture the 3 broad ways we look at valuation

- On the basis of Cash flow
- On the basis of Comparable Companies
- On the basis of the Assets the company has

We follow up in the Appendix with an example for JNJ (Johnson \& Johnson)

If you found this e-book of value and would like to explore valuation more you can sign up at www.stockcalc.com for a free 30 day trial. Now that you are armed with this knowledge you can start to look at companies you are interested in to see if they are under or overvalued. I expect you also have a lot of questions (maybe more questions now?) and we would be happy to help. Start with a trial and look at the videos and walk through on the StockCalc site as they go into detail on how the various calculations occur or drop us a line at info@stockcalc.com and we will get back to you.

## Comprehensive Example:

## Johnson \& Johnson:

We have used JNJ for a number of examples here so it is only appropriate to use it in a comprehensive review. Data is run as of May 5 2017. To receive a full valuation simply enter JNJ in the company textbox along with your email at https://www.stockcalc.com/valureport.aspx

```
Valuation Summary: Johnson & Johnson $123.51 (USD) Close Price as of 05/05/2017
```

Based on the analysis conducted in this report, Johnson \& Johnson, (JNJ:NYS) is found to be Undervalued (refer below to each of the models for detailed calculations and assumptions).

| Company | Johnson \& Johnson |
| :---: | :---: |
| Symbol:Exchange | JNJ:NYS |
| Industry | Healthcare:Drug Manufacturers-Major |
| Close Price/Date | \$123.51 (USD) 05/05/2017 |
| Weighted Average Valuation | \$133.66 (USD) |
| Summary | JNJ:NYS is found to be Undervalued by $8.2 \%$ using the 3 valuation models shown below. |
| Valuation Models Used | Analyst Consensus: \$132.25 (USD) |
| (in order of importance) | Comparables: \$149.63 (USD) |
|  | Adjusted Book Value: $\$ 105.93$ (USD) |
| Valuation Methods Analysis | This company is: |
| Cash Flow Basis: | Undervalued on a Cash Flow Valuation basis |
| Comparable Company Basis: | Undervalued on a Comparable Valuation basis |
| Asset Basis: | Overvalued on an Asset Valuation basis |

## Company Overview (JNJ:NYS USD)



Detailed Company Description

Johnson \& Johnson is a holding company, which is engaged in the research and development, manufacture and sale of products in the health care field within its Consumer, Pharmaceutical and Medical Devices segments.

## Cost of Capital

We have calculated the WACC for JNJ:NYS to be 7.81 based on the following assumptions:

| Component | Value | $\%$ | K | Cost Of |
| :--- | :--- | :--- | :--- | :--- |
| Common Equity | 334713834252 | 93 | Ke | 8.22 |
| Debt (Book Value) | 26989000000 | 7 | Kd | 2.24 |
| Preferred (Book Value) | 0 | 0 | Kp | 0.00 |
| Enterprise Value | 361702834252 | 100 |  |  |
| Weighted Average Cost of Capital |  |  | WACC | 7.81 |

The Company's Beta was calculated as 0.77 using a 60 month time frame and the Dow Jones index.

## Income Statement Projections for <br> JNJ:NYS Johnson \& Johnson

| Line Item USD Millions | 2012 | 2013 | 2014 | 2015 | 2016 | Weighted <br> Average | 2017 | 2018 | 2018 |
| :---: | :---: | :---: | :---: | :---: | :---: | :---: | :---: | :---: | :---: |
| Total Revenue | 67,224 | 71,312 | 74,331 | 70,074 | 71,890 | 100.00 | 75,352 | 78,234 | 82,700 |
| Cost Of Revenue | 21,658 | 22,342 | 22,746 | 21.536 | 21,685 | 30.69 | 20,260 | 20,451 | 21,183 |
| Gross Profit | 45,566 | 48,970 | 51,585 | 48,538 | 50,205 | 69.31 | 55,092 | 57.783 | 61,517 |
| Selling General And Administration | 20.869 | 21,830 | 21,954 | 21,203 | 19,945 | 29.36 | 19.384 | 19,568 | 20,268 |
| Research And Development | 7,665 | 8,183 | 8,672 | 9,046 | 9.095 | 12.28 | 8,107 | 8,183 | 8.476 |
| EBITDA | 17.973 | 20,057 | 24,991 | 23,494 | 24,283 | 32.49 | 27,601 | 30,032 | 32,772 |
| Depreciation and Amortization | 3,666 | 4,104 | 3.895 | 3.746 | 3,754 | 5.34 | 3,955 | 4,615 | 5.414 |
| Operating Expense | 29.697 | 30.593 | 30,626 | 30,473 | 29.040 | 41.94 | 31,603 | 32,812 | 34,685 |
| Operating Income | 15,869 | 18,377 | 20,959 | 18,065 | 21,165 | 27.37 | 23,489 | 24,971 | 26,832 |
| EBIT | 14,307 | 15,953 | 21,096 | 19,748 | 20,529 | 27.14 | 23,646 | 25,417 | 27,359 |
| Interest Income | 64 | 74 | 67 | 128 | 368 | 0.26 | 194 | 202 | 213 |
| Interest Expense | 532 | 482 | 533 | 552 | 726 | 0.83 | 616 | 719 | 844 |
| Pre-Tax Income | 13,775 | 15,471 | 20,563 | 19.196 | 19,803 | 26.31 | 23,030 | 24,697 | 26.515 |
| Tax Provision | 3.261 | 1,640 | 4,240 | 3.787 | 3,263 | 4.73 | 3,500 | 4,085 | 4.791 |
| Net Income | 10.853 | 13,831 | 16,323 | 15,409 | 16,540 | 21.61 | 19,530 | 20,613 | 21,724 |
| Diluted Average Shares | 2,813 | 2,877 | 2,864 | 2,813 | 2.789 |  | 2,752 | 2.727 | 2,700 |
| Diluted EPS | 3.86 | 4.81 | 5.70 | 5.48 | 5.93 |  | 7.10 | 7.56 | 8.05 |
| \# Of Analysts |  |  |  |  |  |  | 7 | 7 | 3 |

## Discounted Cash Flow

Using a Discounted Cash flow model we generate a Value per share for JNJ:NYS of \$153.02 (USD)

| Year | 2017 | 2018 | 2019 | Terminal Growth Rate(\%) |
| :---: | :---: | :---: | :---: | :---: |
|  |  |  |  | 2.8 |
| EBITDA (Cash Flow) | 27601000000 | 30031700000 | 32772400000 | 33690027200 |
| Normalizations \& Adjustments | 0 | 0 | 0 | 0 |
| Normalized EBITDA | 27601000000 | 30031700000 | 32772400000 | 33690027200 |
| Tax Rate (\%) 16.4773 | 4547899573.00 | 4948413304.10 | 5400006665.20 | 5551206851.83 |
| +/- Tax Loss Carry Forward | 0 | 0 | 0 | 0 |
| Net Operating After Tax Cash Flow | 23,053,100,427 | 25,083,286,696 | 27,372,393,335 | 28,138,820,348 |
| Capital Investment Required (Estimate) | -3386400000 | -3386400000 | -3386400000 | -3386400000 |
| Tax Shields on Capital Investment | 401347728 | 401347728 | 401347728 | 401347728 |
| Incremental Working Capital Requirements | -882000000 | -882000000 | -882000000 | -882000000 |
| Discretionary Cash Flow | 19,186,048,155 | 21,216,234,424 | 23,505,341,062 | 24,271,768,076 |
| Terminal Multiple ( 100 /(WACC - Growth Rate )) |  |  |  | 19.98 |
| Capitalized Terminal Value |  |  |  | 484,884,711,393 |


| Year: (For Discounted Calculations) | 1 | 2 | 3 | $3+$ |
| :---: | :---: | :---: | :---: | :---: |
| WACC: <br> 7.81 - User Defined | 7.81 | 7.81 | 7.81 | 7.81 |
| Discounted Annual Cash Flows | 17,796,880,909 | 18,255,134,356 | 18,760,380,805 | 387,002,333,123 |
| Present Value of Discretionary Cash Flow |  |  |  | 54,812,396,069 |
| Discounted Terminal Value |  |  |  | 387,002,333,123 |
| Total Discounted Cash Flow |  |  |  | 441,814,729,192 |
| Present Value of Tax Shields |  |  |  | 0 |
| Redundant Assets |  |  |  | 0 |
| Enterprise Value |  |  |  | 441,814,729,192 |
| Less Interest Bearing Debt |  |  |  | 26989000000 |
| En Block Fair MarketValue(FMV) Equity |  |  |  | 414,825,729, 192 |
| Book Value of Preferred Equity |  |  |  | 0 |
| Value of Common Equity |  |  |  | 414,825,729,192 |
| Number of Fully Diluted Shares Outstanding |  |  |  | 2710891992 |
| Calculated Value Per Share (\$/share) |  |  |  | \$153.02 (USD) |

## Comparable Companies

## (Using Price Based Ratios)

We ran JNJ:NYS against comparable companies in its space and generated a valuation of \$149.61 (USD). The comparable companies included AbbVie (ABBV:NYS), Bristol-Myers Squibb (BMY:NYS), Eli Lilly (LLY:NYS), Merck \& Co (MRK:NYS) and Pfizer (PFE:NYS)

| Company JNJ:NYS | End Date Value | Price Based on Comps | Adjustment Factor (\%) |  |
| :---: | :---: | :---: | :---: | :---: |
| Earnings/Share | $\$ 5.93$ (USD) | \$169.16 (USD) | -16.2 |  |
| Book Value/Share | \$25.98 (USD) | \$224.24 (USD) | -15.4 |  |
| Sales/Share | \$25.78 (USD) | \$109.96 (USD) | 8.0 |  |
| Cash Flow/Share | \$6.73 (USD) | \$117.08 (USD) | -7.3 |  |
| EBITDA/Share | \$8.71 (USD) | \$189.23 (USD) | 0.0 |  |


| JNJ:NYS | Ratios Used | Average Values | ABBV:NYS | BMY:NYS | LLY:NYS | MRK:NYS | PFE:NYS |
| :---: | :---: | :---: | :---: | :---: | :---: | :---: | :---: |
| 20.82 | PE Ratio | 28.53 | 18.17 | 19.46 | 31.81 | 44.21 | 28.99 |
| 4.75 | PB Ratio | 8.63 | 22.64 | 6.41 | 6.46 | 4.26 | 3.39 |
| 4.79 | PS Ratio | 4.27 | 4.19 | 4.71 | 4.11 | 4.36 | 3.95 |
| 18.35 | PCF Ratio | 17.40 | 15.27 | 23.87 | 17.96 | 16.74 | 13.14 |
| 15.58 | EV to EBITDA | 22.85 | 15.17 | 14.83 | 26.64 | 33.89 | 23.72 |

## Adjusted Book Value versus Historical Price to Book

The average the Price to Book ratio for JNJ:NYS for the last 10 years was 4.07 We ran the Adjusted Book Value for JNJ:NYS as follows and see a value of \$26.02 (USD) By multiplying these we get an adjusted valuation of $\$ 105.95$ (USD)

| Line Item | Most Recent Book Value | Estimated FMV | Realizable \% |
| :---: | :---: | :---: | :---: |
| Total Assets | 141208000000 | 141208000000 |  |
| Current Assets | 65032000000 | 65032000000 |  |
| Cash and Cash Equilivents | 18972000000 | 18972000000 | 100.00 |
| Other Short Term Investments | 22935000000 | 22935000000 | 100.00 |
| Receivables | 11699000000 | 11699000000 | 100.00 |
| Inventory | 8144000000 | 8144000000 | 100.00 |
| Prepaid Assets | 3282000000 | 3282000000 | 100.00 |
| Deferred Income Taxes | 0 | 0 | 0.00 |
| Other Current Assets | 0 | 0 | 0.00 |
| Non-Current Assets | 76176000000 | 76176000000 |  |
| Gross PPE | 37773000000 | 37773000000 |  |
| Accumulated Depreciation | -21861000000 | -21861000000 |  |
| Net PPE | 15912000000 | 15912000000 | 100.00 |

## References:

## Literature Cited:

Athanassakos, George. "Equity Valuation: A Guide to Discounted Cash Flow and Relative Valuation Methods" 1995
Canadian Institute of Chartered Business Valuators. "Introductory Business and Security Valuation" 2008.
Canadian Institute of Chartered Business Valuators. "Intermediate Business and Security Valuation" 2008.
Canadian Institute of Chartered Business Valuators. "Advanced Business and Security Valuation" 2008.
Campbell, Ian R. and Johnson, Howard E. "The Valuation of Business Interests" 2001.
Campbell, Ian R., Johnson, Howard E. and Nobes, H. Christopher. "Canada Valuation Service: 2008 Student Edition" 2008.
Damodaran, Aswath: Stern School of Business at New York University: http://pages.stern.nyu.edu/~adamodar/
Investopedia: https://www.investopedia.com

